These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 24341548)

  • 1. Comparison between preoperative and real-time intraoperative planning ¹²⁵I permanent prostate brachytherapy: long-term clinical biochemical outcome.
    Matzkin H; Chen J; German L; Mabjeesh NJ
    Radiat Oncol; 2013 Dec; 8():288. PubMed ID: 24341548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
    Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective comparison of PSA kinetics following two different prostate cancer brachytherapy planning methods: preoperative and real-time intraoperative dosimetry planning.
    Matzkin H; Chen J; Stenger A; Agai R; Mabjeesh NJ
    Urol Oncol; 2012; 30(4):379-85. PubMed ID: 20189847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
    Kollmeier MA; Stock RG; Stone N
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer.
    Zelefsky MJ; Hollister T; Raben A; Matthews S; Wallner KE
    Int J Radiat Oncol Biol Phys; 2000 Jul; 47(5):1261-6. PubMed ID: 10889379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer.
    Merrick GS; Butler WM; Galbreath RW; Lief JH
    Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):41-8. PubMed ID: 11516849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Permanent prostate brachytherapy with or without supplemental external beam radiotherapy as practiced in Japan: outcomes of 1300 patients.
    Yorozu A; Kuroiwa N; Takahashi A; Toya K; Saito S; Nishiyama T; Yagi Y; Tanaka T; Shiraishi Y; Ohashi T
    Brachytherapy; 2015; 14(2):111-7. PubMed ID: 25127123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isotope selection for patients undergoing prostate brachytherapy.
    Cha CM; Potters L; Ashley R; Freeman K; Wang XH; Waldbaum R; Leibel S
    Int J Radiat Oncol Biol Phys; 1999 Sep; 45(2):391-5. PubMed ID: 10487561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of loose versus stranded seeds on biochemical no evidence of disease in patients with carcinoma of the prostate treated with iodine-125 brachytherapy.
    Herbert C; Morris WJ; Hamm J; Lapointe V; McKenzie M; Pickles T; Spadinger I; Keyes M
    Brachytherapy; 2011; 10(6):442-8. PubMed ID: 21398190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Median 5 year follow-up of 125iodine brachytherapy as monotherapy in men agedGómez-Iturriaga Piña A; Crook J; Borg J; Lockwood G; Fleshner N
    Urology; 2010 Jun; 75(6):1412-6. PubMed ID: 20035986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adaptive cone-beam CT planning improves long-term biochemical disease-free survival for
    Peters M; Smit Duijzentkunst DA; Westendorp H; van de Pol SMG; Kattevilder R; Schellekens A; van der Voort van Zyp JRN; Moerland MA; van Vulpen M; Hoekstra CJ
    Brachytherapy; 2017; 16(2):282-290. PubMed ID: 28110899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of high dose rate afterloading brachytherapy boost to conventional external beam radiation therapy for initial and locally advanced prostate cancer.
    Pellizzon AC; Nadalin W; Salvajoli JV; Fogaroli RC; Novaes PE; Maia MA; Ferrigno R
    Radiother Oncol; 2003 Feb; 66(2):167-72. PubMed ID: 12648788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gleason 7 prostate cancer treated with low-dose-rate brachytherapy: lack of impact of primary Gleason pattern on biochemical failure.
    Stock RG; Berkowitz J; Blacksburg SR; Stone NN
    BJU Int; 2012 Nov; 110(9):1257-61. PubMed ID: 22571680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH; Allen Z; Adamovich E
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):32-43. PubMed ID: 15629591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.
    Ho AY; Burri RJ; Cesaretti JA; Stone NN; Stock RG
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):16-22. PubMed ID: 19289266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Permanent prostate brachytherapy and short-term androgen deprivation for intermediate-risk prostate cancer in Japanese men: outcome and toxicity.
    Yamada Y; Masui K; Iwata T; Naitoh Y; Yamada K; Miki T; Okihara K
    Brachytherapy; 2015; 14(2):118-23. PubMed ID: 25304650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure.
    Ko EC; Stone NN; Stock RG
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):600-7. PubMed ID: 21985944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transperineal permanent seed implantation of "low-risk" prostate cancer: 5-year-experiences in 118 patients.
    Block T; Czempiel H; Zimmermann F
    Strahlenther Onkol; 2006 Nov; 182(11):666-71. PubMed ID: 17072525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term biochemical control and cause-specific survival in men with Gleason grade Group 4 and 5 prostate cancer treated with brachytherapy and external beam irradiation.
    Stone NN; Skouteris V; Stock RG
    Brachytherapy; 2020; 19(3):275-281. PubMed ID: 32217039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does hormonal manipulation in conjunction with permanent interstitial brachytherapy, with or without supplemental external beam irradiation, improve the biochemical outcome for men with intermediate or high-risk prostate cancer?
    Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
    BJU Int; 2003 Jan; 91(1):23-9. PubMed ID: 12614244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.